Abstracts Archive - Page 32 of 2607 - ACR Meeting Abstracts

Abstract Number: 0206 • ACR Convergence 2025
Prospective Controlled Study of Humoral Response to Recombinant Zoster Vaccine in Cyclophosphamide-Treated Autoimmune Rheumatic Disease Patients: No Additional Impairment Compared to Other Immunosuppressive Therapies
Nadia Emi Aikawa¹, Julia Medeiros², Sandra G Pasoto³, Ana C Medeiros-Ribeiro³, Luciana Parente Costa Seguro⁴, Ana Paula Luppino-Assad⁵, Emily Figueiredo Neves Yuki⁶, Lissiane Guedes⁷, Clovis Artur Silva⁸ and Eloisa Bonfa⁴, ¹Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SAO PAULO, Brazil, ⁶Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Recombinant zoster vaccine (RZV), represents a major advancement in the prevention of herpes zoster in autoimmune rheumatic diseases (ARD) patients. However, RVZ efficacy depends…
Abstract Number: 0029 • ACR Convergence 2025
A Novel B Cell Subpopulation Characteristic of IgA Vasculitis Identified by Single-Cell RNA Sequencing
Joao Carlos Batista-Liz¹, María Sebastián Mora-Gil², Evan Troendle³, Oisin Cappa³, Maite Leonardo⁴, Ana Peñalba⁴, Luis mARTIN pENAGOS⁵, Ligia Gabrie-Rodriguez⁶, Rafael Gálvez Sánchez⁶, Jose Luis Callejas⁷, Belen Sevilla⁸, Diego de Argila⁹, Esther Vicente-Rabaneda⁹, Santos Castañeda¹⁰, David Simpson³, Ricardo Blanco¹¹, Verónica Pulito Cueto¹ and Raquel Lopez Mejias¹, ¹IDIVAL, Santander, Spain, ²Immunopathology Group, IDIVAL, Santander, Spain, ³Queens University, Wellcome-Wolfson Institute for Experimental Medicine, Belfast, United Kingdom, ⁴Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Immunopathology Group, IDIVAL and Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁷Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, ⁸Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ⁹Hospital Universitario de la Princesa, Madrid, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: IgA vasculitis (IgAV) is a systemic small-vessel vasculitis characterized by immune complex deposition containing aberrantly glycosylated IgA1. While its clinical manifestations are well defined…
Abstract Number: 0181 • ACR Convergence 2025
Launch of the National Tele-Rheumatology Program (NTRP) to Expand Rheumatology Care to Rural Veterans
Cherish Wilson¹, Catherine Nasrallah², Gary Tarasovsky³, Alicia Hamblin⁴, Asia Williams⁵, Broderick Flynn⁵, Bernard Ng⁶ and gabriela Schmajuk⁷, ¹UCSF / SFVA, San Francisco, CA, ²University of California San Francisco (UCSF), San Francisco, CA, ³SFVA, San Francisco, ⁴UCSF, San Francisco, CA, ⁵Lexington VA, Lexington, ⁶Lexington VA, University of Washington, Seattle, ⁷University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Given the nationwide shortage of rheumatologists, particularly in rural areas, many Veterans Affairs (VA) facilities have struggled to hire or retain specialists, resulting in…
Abstract Number: 0151 • ACR Convergence 2025
Post-COVID Decline in Systemic Lupus Erythematosus Mortality in the United States: A National Analysis from 2014 to 2023
Ghassan Makhoul¹, Aziz-ur-Rahman Khalid², Islam Rajab¹, Hasan Munshi¹, Emmanuel Olumuyide³, MD Walid Akram Hussain¹, Aqsa Sorathia¹, Reshma John¹, Ahmed Huzien¹, ivan Mercado¹, Nargis Mateen⁴ and Robert Lahita², ¹St. Josephs University Medical Center, Paterson, ²St. Josephs University Medical Center, Wayne, NJ, ³Advocate Illinois Masonic Medical Center, Chicago, ⁴St. Josephs University Medical Center, Paterson, NJ
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease with high morbidity and mortality. The impact of the COVID-19 pandemic on SLE-related deaths…
Abstract Number: 0125 • ACR Convergence 2025
The IFN Signature is Less Pronounces in Primary Antiphospholipid Syndrome Compared with other Systemic Autoimmune Diseases
Dionysis Nikolopoulos¹, Konstantinos Charitidis², Julius Lindblom², Maria O Borghi³, Guillermo Barturen⁴, Marta Alarcon-Riquelme⁵, Lorenzo Beretta⁶ and Ioannis Parodis⁷, ¹Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³IRCCS, Istituto Auxologico Italiano, Milan, Italy, ⁴Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁵Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁶Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ⁷Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden
Background/Purpose: Primary antiphospholipid syndrome (pAPS) is an autoimmune disease that, unlike many other autoimmune diseases, commonly presents with thrombotic events rather than inflammatory manifestations. A…
Abstract Number: 0165 • ACR Convergence 2025
Per-Protocol Analysis of the Effectiveness of GLP1 Agonists Against SGLT2 Inhibitors on Osteoarthritis Outcomes
Nene Ukonu¹, David Felson², Michael LaValley³ and S. Reza Jafarzadeh⁴, ¹Boston University School of Public Health, Boston, MA, ²Boston University, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Boston University Chobanian & Avedisian School of Medicine, Boston, MA
Background/Purpose: Anti-diabetic medications often have effects on other conditions. GLP1 agonists (GLP1a) have shown protective effects on OA outcomes in trials and short-term trial emulations,…
Abstract Number: 0107 • ACR Convergence 2025
Role of Achilles Elastography in Differentiating Patients with Early Psoriatic Arthritis
IRENE MARTIN MARTIN¹, CARMEN SAN JOSE MENDEZ², SONIA JIMENEZ BARRIOS³, ELENA MARTIN FERNANDEZ⁴, JULIA MIRANDA MANZANO⁵, DIEGO DIOS SANTOS⁶, JORGE GONZALEZ MARTIN⁷, PABLO ZURITA PRADA⁷, MONICA VAZQUEZ DIAZ⁸ and CARLOS GUILLEN-ASTETE⁹, ¹HOSPITAL VIRGEN DE LAS NIEVES, GRANADA, ²Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain, ³Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁴HOSPITAL UNIVERSITARIO RAMON Y CAJAL, MADRID, ⁵FACULTAD BIOMEDICINA, MADRID, ⁶HOSPITAL DE VERÍN, OURENSE, ⁷HOSPITAL UNIVERSITARIO HM SANCHINARRO, MADRID, ⁸HOSPITAL UNIVERSITARIO HLA MONCLOA, MADRID, ⁹H.U Ramón y Cajal, Madrid, Spain
Background/Purpose: Elastography (EL) is an imaging technique that evaluates the biomechanical properties of tissues. Pathological tissues have different elastic properties compared to healthy tissues.In diseases…
Abstract Number: 0117 • ACR Convergence 2025
Are Thrombotic or Obstetric Events Associated with Additional Clinical Domains in Triple Antiphospholypid Syndrome?
Cristina Rocamora-Gisbert¹, Francina salabert-Carreras², Raquel Ugena-García³, Cristina Calomarde-Gómez³, Clara Churtichaga Domenech², Judith Vidal-Ripoll², Laia Gifre-Sala², Agueda Prior-Español², Annika Nack¹, Susana Holgado⁴, Maria Aparicio¹, Melania Martínez-Morillo², LOURDES MATEO SORIA⁵, Anne Riveros frutos¹, Ivette Casafont-Solé³ and Judit Font-Urgelles³, ¹Hospital Germans Trias i Pujol, Barcelona, Spain, ²Hospital Germans Trias i Pujol, Barcelona, ³Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁴Hospital Germans Trias i Pujol, Barcelona, Catalonia, Spain, ⁵HOSPITAL GERMANS TRIAS I PUJOL, BADALONA, Spain
Background/Purpose: It is known that triple positive antiphospholipid syndrome (APS-TP) is related to an increased presence of thrombotic and obstetric manifestations. Triple positivity is referred…
Abstract Number: 0184 • ACR Convergence 2025
Neurocognitive Complications of Lupus: A Multidisciplinary Program Model for Advanced Diagnostics, Management, and Clinical Research
Douglas Wilcox¹, Matthew Baum², Sophie Lebiedz², John Sullivan², Margaret Naclerio², Jonathan Zurawski², Bonnie Glanz², Rohit Bakshi², Tanuja Chitnis², Shamik Bhattacharyya³ and Karen H. Costenbader⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, Malden, MA, ⁴Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Neurological symptoms in lupus are common and occur in the majority of patients with SLE. Although neuropsychiatric lupus (NPSLE) can involve the entire nervous…
Abstract Number: 0197 • ACR Convergence 2025
Rheumatoid arthritis (RA) patients who screen positive for anxiety, depression, and/or fibromyalgia are more likely to report problems with sleeping, memory, and/or social activities than to have an abnormal rheumatoid factor or ACPA
Theodore Pincus¹, Juan Schmukler¹ and Tengfei Li², ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: A symptom checklist and screening indices for anxiety (ANX), depression (DEP), and/or fibromyalgia (FM) on patient questionnaires such as a multidimensional health assessment questionnaire…
Abstract Number: 0171 • ACR Convergence 2025
The Association Between Short-Term Trajectory Of Atmospheric Particulate Matter 10 (PM10) Concentration And Hyperuricemia
Sunggun Lee¹, Minyoung Her¹, Seong-HO Kim¹, Yong-Gil Kim² and Ji Seon Oh², ¹Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul, Republic of Korea
Background/Purpose: The association between high atmospheric particulate matter concentration and gout flare has been reported1, but the causality and mechanism of this association remain unknown.…
Abstract Number: 0105 • ACR Convergence 2025
Inflammatory Cytokines, Matrix Metalloproteinases and Bone Markers Expressions Are Modulated in the Joints in the Chronic Murine Model of Imiquimod-Induced Psoriasis
Guillaume LARID¹, Cassandre Dumonteix Moreau², Adrien JAMAI², Hanitriniaina Rabeony², Jean Claude LECRON², Elisabeth Gervais¹, Jean François JEGOU² and franck MOREL², ¹Poitiers University Hospital - Poitiers University - LITEC Laboratory UR ¹⁵⁵⁶⁰, Poitiers, France, ²Poitiers University - LITEC Laboratory UR ¹⁵⁵⁶⁰, Poitiers, France
Background/Purpose: Psoriatic disease is a systemic inflammatory condition which encompasses both cutaneous psoriasis (PsO), psoriatic arthritis (PsA) and multiple comorbidities. The chronic Imiquimod (IMQ) induced…
Abstract Number: 0204 • ACR Convergence 2025
Immunogenicity and safety summary for the chikungunya virus-like particle vaccine development programme
Lauren Tindale¹, Jason Richardson¹, Deborah Anderson¹, Jason Mendy², Sufia Muhammad², Tobi Loreth¹, Victoria Jenkins³, Krystal Valenzuela⁴, Benedetto Simone⁵, Patrick Ajiboye² and Lisa Bedell⁴, ¹Bavarian Nordic Canada Inc., Toronto, Canada, ²Bavarian Nordic, Inc., San Diego, ³Bavarian Nordic Belgium, Brussels, Belgium, ⁴Bavarian Nordic, Inc., Durham, ⁵Bavarian Nordic Berna GmbH, Thoerishaus, Switzerland
Background/Purpose: Chikungunya virus (CHIKV) is a threat to public health and a risk for travellers to endemic countries. Typical acute symptoms include fever, arthralgia, myalgia,…
Abstract Number: 0011 • ACR Convergence 2025
KT502, a novel CD19-directed TCE (T-cell engager), leads to rapid and deep B-cell depletion with low cytokine release
Min Bao, John Wang, Jay Zhao and Weihao Xu, Kali Therapeutics, San Mateo, CA
Background/Purpose: Chimeric antigen receptor T-cell (CAR-T) therapies targeting CD19 have shown unprecedented effects in treatment-resistant autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis…
Abstract Number: 0172 • ACR Convergence 2025
Cancer Screening for Patients with Rheumatic Diseases: A Scoping Review
Teresa Xiao¹, Namrata Singh² and Pankti Reid³, ¹University of Chicago, Chicago, IL, ²University of Washington, Bellevue, WA, ³University of Chicago Medical Center, Chicago, IL
Background/Purpose: There is minimal guidance on specific cancer screening practices for rheumatic diseases (RDs) other than for myositis. The aim of this scoping review was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].